# Diabetes Medication Support

Discontinue treatment if the initial body weight has not decreased by at least 5% after 12 weeks of using 3.0 mg/day. In individuals with type 2 diabetes mellitus: do not use in combination with another GLP-1 agonist. When combined with a sulfonylurea derivative or insulin, consider reducing the sulfonylurea or insulin dose to reduce the risk of hypoglycemia; self-monitoring of blood glucose levels is necessary. For elderly patients (? 65 years), renal and liver function impairment: No dose adjustment is needed for elderly patients and mild or moderate renal or liver impairment. Use in elderly patients ? 75 years, severe renal impairment (creatinine clearance < 30 ml/min, including end-stage renal disease) or severe liver impairment is not recommended. Saxenda: Starting dose s.c. 0.6 mg once daily, increase in steps of 0.6 mg with intervals of at least one week to a maintenance dose of 3.0 mg once daily or to the maximum tolerated dose max. 3.0 mg/day. Discontinue and reconsider treatment if the patient has not lost at least 4% of their BMI or BMI z-score (standard deviation score) after 12 weeks of using the maximum tolerated maintenance dose.

We offer programs and services to help lower the cost of your diabetes medication or provide it free if you qualify, particularly for insulin. Find out whether your insurance covers your medication online in minutes. You may also get an estimated cost.

Find inspiration and motivation for staying active, eating healthy, and building up your diabetes knowledge with education and resources from NovoCare.

Xultophy 100/3.6 is a once-daily injectable medication that should be taken at the same time each day. Adjusting your dose based on your blood sugar readings may be a step toward reaching your A1C goal.

See how starting Xultophy 100/3.6 and tracking your blood sugar can help you reach your A1C goal. Talk to your health care provider about how to adjust your dose based on your blood sugar readings.

Taking a single daily dose of Xultophy 100/3.6 showed similar A1C results to 1 long-acting and up to 4 mealtime insulin injections.

Xultophy 100/3.6 (insulin degludec and liraglutide) injection 100 units/mL and 3.6 mg/mL is an injectable prescription medicine that contains 2 diabetes medicines, insulin degludec, 100 units/mL, and liraglutide, 3.6 mg/mL, that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Before using Xultophy 100/3.6, talk to your health care provider about low blood sugar and how to manage it.

The most common side effects of Xultophy 100/3.6 may include stuffy or runny nose, sore throat, headache, nausea, diarrhea, increased blood levels of lipase, and upper respiratory tract infection.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.